by May Murra Over the past three decades several novel zoonotic infectious diseases have emerged due to human activities such as changes in ecosystems, land-use, intensification of agriculture, urbanization and international travel and trade. A collaboration involving animal, human and Read more…
by Eleni Vergadi, Young ISSAD committee memberAssist. Professor of Paediatrics, Medical School, University of Crete Time after time, we hear the stories of mothers who have experienced loss of their newborn babies or severe manifestations caused by infections they had Read more…
Maternal colonization by Group B Streptococcus (GBS) can lead to severe infection in neonates and has also been associated with prematurity and stillbirth. Bronner P. Gonçalves’s comments on research into maternal Group B Strep colonisation. Bronner P. Gonçalves’s research, recently Read more…
By Javairia Khalid, Lecturer, The Aga Khan University, Pakistan Group B streptococcus (GBS) or Streptococcus agalactiae is a type of bacteria that commonly inhabits the gastrointestinal and genital tracts of healthy individuals. While it is a commensal organism in most Read more…
Vaccinating pregnant mothers could avert 31,000 deaths and save $385m in healthcare costs, it is estimated; A global maternal immunisation programme for group B Streptococcus – Strep B – would save millions of dollars in healthcare costs by reducing death Read more…
We are pleased to announce that Meningitis Research Foundation’s biennial conference will be held on the 7th – 8th November 2023 at the British Museum in London. This will be our fourteenth international conference and will bring world leading experts Read more…
Why do we need to step forward towards a maternal GBS-vaccine? By May Murra, Aarhus University Hospital, Denmark and Dr Eleni Vergadi, University of Crete, Medical School Global impact of GBS in mothers, neonates, and infants Globally, around 20% of Read more…
By Javairia Khalid, Lecturer, The Aga Khan University, Pakistan Dr Javairia Khalid, a member of the ‘Young ISSAD’ Committee, has created a handy infographic regarding the symptoms of GBS disease in newborns compared to people of other ages who get Read more…
MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Read more…
Abstracts are now being accepted for the above annual virtual conference, which brings together experts from the UK and around the world to share knowledge and discuss the latest developments in this field. This conference will provide a platform for Read more…